加纳、肯尼亚和马拉维RTS,S/AS01E疟疾疫苗第三剂后1年内的安全性(EPI-MAL-003):一项4期队列事件监测研究
EPI-MAL-003是一项正在进行的4期疾病监测研究,在加纳、肯尼亚和马拉维常规医疗实践中前瞻性监测队列事件并开展医院监测,纳入44 912名儿童比较暴露与未暴露集群。结果显示接种与未接种儿童在全面性惊厥发作、肠套叠、病因确认脑膜炎、脑型疟和全因死亡率方面无证据表明接种增加风险,未发现新的安全风险。
要点
- 研究纳入44 912名儿童(暴露集群22 508名,未暴露集群22 404名),比较RTS,S/AS01E接种与未接种儿童的安全性。
- 病因确认脑膜炎在接种儿童和未接种儿童中各报告1例,调整国家后发病率比为0·96(95%CI 0·06-15·34;p=0·98)。
- 作者结论为无证据表明接种与脑膜炎、脑型疟或死亡率风险增加相关,未发现新的安全风险。
核心结论
- 作者结论为无证据表明接种与接种儿童脑膜炎、脑型疟或死亡率风险增加相关,未发现新的安全风险。
研究设计与样本
- EPI-MAL-003是一项正在进行的4期疾病监测研究,采用前瞻性队列事件监测和医院监测,在加纳、肯尼亚和马拉维常规医疗实践中开展并完全嵌入疟疾疫苗实施计划(MVIP)。
- 研究设计取决于集群随机疫苗实施;主动监测中从暴露集群(提供RTS,S/AS01E)和未暴露集群纳入18个月以下儿童。
- 共同主要终点为 predefined 特别关注不良事件的发生和病因确认脑膜炎;报告基础免疫程序(三剂)后长达1年的主要和次要安全性结果;研究注册号ClinicalTrials.gov NCT03855995。
- 分析集共44 912名儿童(加纳19 993名、肯尼亚11 990名、马拉维12 929名)用于集群随机比较:暴露集群22 508名,未暴露集群22 404名。
主要发现
- 全面性惊厥发作和肠套叠的发病率(每10万人年)在接种与未接种儿童之间相似。
- 病因确认脑膜炎报告2例:暴露集群接种RTS,S/AS01E儿童中1例肺炎链球菌细菌性脑膜炎,未暴露集群未接种儿童中1例人疱疹病毒6型病毒性脑膜炎;两例均发生在接种后12个月内,接种儿童发病率为4·1(95%CI 0·1-23·0)/10万人年,未接种儿童为4·0(95%CI 0·1-22·6)/10万人年,调整国家后发病率比(IRR)为0·96(95%CI 0·06-15·34;p=0·98)。
- 脑型疟在暴露集群20 639名接种RTS,S/AS01E儿童中报告4例(<0·1%),在未暴露集群22 137名未接种儿童中报告2例(<0·1%);基础接种后12个月内分别发生3例和2例(IRR 1·43,95%CI 0·24-8·58,p=0·70)。
- 全因死亡率发病率在接种儿童为659·7(95%CI 561·5-770·3),未接种儿童为724·5(95%CI 622·3-838·8),男女童发病率相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: RTS,S/AS01E has been successfully administered to over two million children since 2019 through the Malaria Vaccine Implementation Programme (MVIP). In this Article, we report the safety results of a study evaluating RTS,S/AS01E safety and effectiveness in real-world settings. METHODS: EPI-MAL-003 is an ongoing phase 4 disease surveillance study with prospective cohort event monitoring and hospital-based surveillance, done in the setting of routine health-care practice in Ghana, Kenya, and Malawi and fully embedded in the MVIP. The study design was dependent on the cluster-randomised vaccine implementation. In active surveillance, we enrolled children younger than 18 months from exposed (where RTS,S/AS01E was offered) and unexposed clusters. The coprimary endpoints were the occurrence of predefined adverse events of special interest and aetiology-confirmed meningitis. We report primary and secondary safety results up to 1 year after the primary vaccine schedule (three doses). The study is registered with ClinicalTrials.gov, NCT03855995. FINDINGS: The first participant was enrolled on March 21, 2019. The cutoff date for the current analysis was 1 year after the third RTS,S/AS01E dose for each participant. In total, 44 912 children (19 993 in Ghana, 11 990 in Kenya, and 12 929 in Malawi) were included in the analysis set for the cluster-randomised comparison: 22 508 from exposed clusters and 22 404 from unexposed clusters. Incidence rates (expressed per 100 000 person-years) for generalised convulsive seizures and intussusception were similar between vaccinated and unvaccinated children. Aetiology-confirmed meningitis was reported in two children: one case of bacterial meningitis due to Streptococcus pneumoniae in an RTS,S/AS01E-vaccinated child in the exposed clusters, and one case of viral meningitis due to human herpesvirus 6 in an unvaccinated child in the unexposed clusters. Both cases occurred within 12 months after vaccination in children in the cluster-design analysis set, leading to incidence rates of 4·1 (95% CI 0·1-23·0) per 100 000 person-years in RTS,S/AS01E-vaccinated children and 4·0 (0·1-22·6) per 100 000 person-years in unvaccinated children, and a country-adjusted incidence rate ratio (IRR) of 0·96 (95% CI 0·06-15·34; p=0·98). Cerebral malaria cases were reported for four (<0·1%) of 20 639 RTS,S/AS01E-vaccinated children in the exposed clusters and two (<0·1%) of 22 137 unvaccinated children in the unexposed clusters. These included three and two cases occurring within 12 months after the primary vaccination, in RTS,S/AS01E-vaccinated children and unvaccinated children, respectively (IRR 1·43, 95% CI 0·24-8·58, p=0·70). Incidence rates for all-cause mortality were 659·7 (95% CI 561·5-770·3) in vaccinated children versus 724·5 (622·3-838·8) in unvaccinated children, with similar incidence rates for boys and girls. INTERPRETATION: We found no evidence of vaccination being associated with an increased risk of meningitis, cerebral malaria, or mortality among vaccinated children, and no new safety risks were identified. FUNDING: GSK.
引用
- Haine V, Oneko M, Debois M, et al. Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study. Lancet Glob Health. 2025. PMID: 40288377. doi:10.1016/S2214-109X(25)00096-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。